{Reference Type}: Case Reports
{Title}: Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.
{Author}: Ahangar Davoodi M;Daneshmand MA;Rezaei T;
{Journal}: J Diabetes
{Volume}: 16
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 4.53
{DOI}: 10.1111/1753-0407.13570
{Abstract}: Highlights A persistent glycosuria alongside hypoglycemia in pediatric type 1 diabetes mellitus needs further evaluation. Morning hypoglycemia is a limiting side effect of sodium glucose transporter 2 (SGLT2) inhibitors in children younger than 5 years old. SLC5A2 mutation functioning as a SGLT2 inhibitor can result in acceptable range of glycated hemoglobin in younger children and lower required doses of insulin.